Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: effects are uncertain (search done 23 April 2020)
Citation: Valk SJ, Piechotta V, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a rapid review. Cochrane Database of Systematic Reviews 2020;(5):CD013600
What is this? Convalescent plasma and hyperimmune immunoglobulin have been suggested as possible treatments for COVID-19.
In this Cochrane Rapid Review, the authors searched for studies that had evaluated convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19, irrespective of disease severity, age, gender or ethnicity. They did not restrict their searches by type or language of publication and searched for articles published between 1 January 2019 and 23 April 2020. They included 7 case‐series and one prospectively planned, single‐arm intervention study (total: 32 participants), and rated these as very low‐certainty evidence, with all studies being at high risk of bias. The authors also identified a further 48 ongoing studies evaluating convalescent plasma (47 studies) or hyperimmune immunoglobulin (1), of which 22 are randomized trials. A podcast for the review is available here [https://www.cochrane.org/podcasts/10.1002/14651858.CD013600]
What was found: At the time of this review, the available research showed that the benefits and harms of convalescent plasma or hyperimmune immunoglobulin are uncertain. The review will be updated as a living systematic review and these updates are expected to show different results to the current results.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.